目的 探討甲狀腺全切除術(shù)治療甲狀腺良性疾病的安全性和臨床意義。
方法 對88例甲狀腺良性疾病患者進行甲狀腺全切除術(shù)，并對手術(shù)并發(fā)癥進行分析。
結(jié)果 首次甲狀腺全切除術(shù)暫時性甲狀旁腺功能低下和暫時性喉返神經(jīng)損傷的發(fā)生率分別為2.5%和1.2%，再次手術(shù)的并發(fā)癥明顯增高，分別為28.6%（P＜0.05）和28.6%（P＜0.01）。術(shù)后患者均未發(fā)生永久性甲狀旁腺功能低下和永久性喉返神經(jīng)損傷。
結(jié)論 首次甲狀腺全切除術(shù)安全可行，能避免因組織殘留所致的病變復(fù)發(fā)，降低再手術(shù)率。
引用本文： 蘇清華,潘小明,吳宣林. 甲狀腺全切除術(shù)治療甲狀腺良性疾病. 中國普外基礎(chǔ)與臨床雜志, 2004, 11(6): 493-495. doi: 復(fù)制
| 1. | Friguglietti CU, Lin CS, Kulcsar MA. Total thyroidectomy for benign thyroid disease [Ｊ]. Laryngoscope, 2003; 113(10)∶ 1820. |
| 2. | Bellantone R, Lombardi CP, Bossola M, et al. Total thyroidectomy for management of benign thyroid disease: review of 526 cases. World J Surg, 2002; 26(12)∶1468. |
| 3. | Muller PE, Kabus S, Robens E, et al. Indications, risks, and acceptance of total thyroidectomy for multinodular benign goiter [Ｊ]. Surg Today, 2001; 31(11)∶958. |
| 4. | 李樹玲. 甲狀腺外科的現(xiàn)狀與展望 [Ｊ]. 中國普外基礎(chǔ)與臨床雜志, 2003; 10(3)∶209. |
| 5. | 張德恒. 碘源性甲狀腺良性疾病外科治療的再認識 [Ｊ]. 外科理論與實踐, 2003; 8(4)∶295. |
| 6. | Menegaux F, Turpin G, Dahman M, et al. Secondary thyroidectomy in patients with prior thyoid surgery for benign disease: a study of 203 cases [Ｊ]. Surgery, 1999; 125(3)∶479. |
| 7. | Reeve TS, Delbridge L, Cohen A, et al. Total thyroidectomy. The preferred option for multinodular goiter [Ｊ]. Ann Surg, 1987; 206(6)∶782. |
| 8. | Rojdmark J, Jarhult J. High long term recurrence rate after subtotal thyroidectomy for nodular goitre [Ｊ]. Eur J Surg, 1995; 161(10)∶725. |
| 9. | Kasuga Y, Sugenoya A, Kobayashi S, et al. Significance of values of thyrotropin binding inhibitor immunoglobulins and appearance of intrathyroidal lymphocytes at subtotal thyroidectomy for Graves’ disease [Ｊ]. J Am Coll Surg, 1994; 178(6)∶589. |
| 10. | Kasuga Y, Kobayashi S, Fujimori M, et al. Changes in thyroid function and immunological parameters long after subtotal thyroidectomy for Graves’ disease [Ｊ]. Eur J Surg, 1998; 164(3)∶173. |
- 1. Friguglietti CU, Lin CS, Kulcsar MA. Total thyroidectomy for benign thyroid disease [Ｊ]. Laryngoscope, 2003; 113(10)∶ 1820.
- 2. Bellantone R, Lombardi CP, Bossola M, et al. Total thyroidectomy for management of benign thyroid disease: review of 526 cases. World J Surg, 2002; 26(12)∶1468.
- 3. Muller PE, Kabus S, Robens E, et al. Indications, risks, and acceptance of total thyroidectomy for multinodular benign goiter [Ｊ]. Surg Today, 2001; 31(11)∶958.
- 4. 李樹玲. 甲狀腺外科的現(xiàn)狀與展望 [Ｊ]. 中國普外基礎(chǔ)與臨床雜志, 2003; 10(3)∶209.
- 5. 張德恒. 碘源性甲狀腺良性疾病外科治療的再認識 [Ｊ]. 外科理論與實踐, 2003; 8(4)∶295.
- 6. Menegaux F, Turpin G, Dahman M, et al. Secondary thyroidectomy in patients with prior thyoid surgery for benign disease: a study of 203 cases [Ｊ]. Surgery, 1999; 125(3)∶479.
- 7. Reeve TS, Delbridge L, Cohen A, et al. Total thyroidectomy. The preferred option for multinodular goiter [Ｊ]. Ann Surg, 1987; 206(6)∶782.
- 8. Rojdmark J, Jarhult J. High long term recurrence rate after subtotal thyroidectomy for nodular goitre [Ｊ]. Eur J Surg, 1995; 161(10)∶725.
- 9. Kasuga Y, Sugenoya A, Kobayashi S, et al. Significance of values of thyrotropin binding inhibitor immunoglobulins and appearance of intrathyroidal lymphocytes at subtotal thyroidectomy for Graves’ disease [Ｊ]. J Am Coll Surg, 1994; 178(6)∶589.
- 10. Kasuga Y, Kobayashi S, Fujimori M, et al. Changes in thyroid function and immunological parameters long after subtotal thyroidectomy for Graves’ disease [Ｊ]. Eur J Surg, 1998; 164(3)∶173.